NDA 011153 · Pfizer
Medrol
Methylprednisolone · Oral · Corticosteroid
NovelLast checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1957
Oct 24, 1957
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,078
579 Phase 3, 236 recruiting
FAERS reports
124,181
110,690 serious, 19,405 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 24, 1957 Original approval · Type 1 - New Molecular Entity
6 products under this application
- MEDROL · METHYLPREDNISOLONE 24MG · TABLET, ORAL · Discontinued
- MEDROL · METHYLPREDNISOLONE 16MG · TABLET, ORAL · Prescription · TE AB
- MEDROL · METHYLPREDNISOLONE 4MG · TABLET, ORAL · Prescription · TE AB
- MEDROL · METHYLPREDNISOLONE 32MG · TABLET, ORAL · Prescription · TE AB
- MEDROL · METHYLPREDNISOLONE 8MG · TABLET, ORAL · Prescription · TE AB
- MEDROL · METHYLPREDNISOLONE 2MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Methylprednisolone" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Steroids In caRdiac Surgery Trial (SIRS Trial)Pivotal-lookingStatus unknown
Population Health Research InstituteAcademic, hospital or other
NCT00427388 · 7,507 participants · Start Jun 2007 · Primary completion Feb 2014
Drug: Methylprednisolone · For: Cardiac Surgical Procedures; Cardiopulmonary Bypass; Systemic Inflammatory Response Syndrome
Sites: Hamilton, Canada
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Prehospital Pulse-dose Glucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2 - The PULSE-MI 2 TrialPivotal-lookingRecruiting
Thomas EngstromAcademic, hospital or other
NCT07478003 · 5,204 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 20, 2031
Drug: Methylprednisolone 250 mg; NaCl (0,9%) · For: STEMI - ST Elevation Myocardial Infarction
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use18,660
- drug ineffective14,392
- fatigue6,387
- nausea6,032
- pain5,898
- headache5,777
- pneumonia5,729
- pyrexia5,721
- dyspnoea5,449
- arthralgia5,351
- diarrhoea5,294
- condition aggravated5,023
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 825 |
| 2005 | 878 |
| 2006 | 944 |
| 2007 | 826 |
| 2008 | 1,124 |
| 2009 | 1,138 |
| 2010 | 1,855 |
| 2011 | 2,377 |
| 2012 | 2,922 |
| 2013 | 2,671 |
| 2014 | 3,195 |
| 2015 | 3,989 |
| 2016 | 4,632 |
| 2017 | 5,753 |
| 2018 | 8,014 |
| 2019 | 9,407 |
| 2020 | 12,161 |
| 2021 | 11,536 |
| 2022 | 11,383 |
| 2023 | 10,448 |
| 2024 | 10,700 |
| 2025 | 10,662 |
| 2026 | 6,733 |
Recalls
1 FDA enforcement reports for this application.
Jan 15, 2026 · Class II · Ongoing
Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Medrol (Methylprednisolone)
2024 spending
$10K
Beneficiaries
737
898 claims
Per beneficiary
$13
$0.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $181,016 |
| 2021 | $53,242 |
| 2022 | $13,626 |
| 2023 | $10,821 |
| 2024 | $9,693 |
Part B: Medrol* (MethylprednIsolone*) · HCPCS J7509
2024 spending
$5K
Beneficiaries
99
663 claims
Per beneficiary
$50
2024 ASP limit $0.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,904 |
| 2021 | $8,711 |
| 2022 | $7,088 |
| 2023 | $5,364 |
| 2024 | $4,907 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia.
Meduri GU, Shih MC, Bridges L, et al. · Intensive Care Med 2022 · Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S.
- Methylprednisolone, dexamethasone or hydrocortisone for acute severe pediatric asthma: does it matter?
Doymaz S, Ahmed YE, Francois D, et al. · J Asthma 2022 · Randomized Controlled Trial
- Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.
Jayne DR, Gaskin G, Rasmussen N, et al. · J Am Soc Nephrol 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
Steinberg KP, Hudson LD, Goodman RB, et al. · N Engl J Med 2006 · Multicenter Study, Randomized Controlled Trial
- A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
Beck RW, Cleary PA, Anderson MM, et al. · N Engl J Med 1992 · Clinical Trial, Comparative Study
- Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial.
Hill KD, Kannankeril PJ, Jacobs JP, et al. · N Engl J Med 2022 · Randomized Controlled Trial, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.